This could be an event of major historical significance.
Everyone says the OPC (one-person company) doesn't hold up.
But today, company A announced it acquired a one-person pharmaceutical company.
The founder of Mithril used Claude and 11 external labs to collaborate. In less than 18 months, they advanced a potential therapy for a certain muscular atrophy disease from concept to encouraging results in mice.
The drug is expected to be ready to begin human clinical trials as early as the end of 2028.
Company A has rarely made acquisitions before, but completed four deals in the first half of 2026. In April it acquired Coefficient Bio, a team of fewer than 10 people, for about $400 million in all stock; in May it acquired Stainless (an SDK and MCP server generator), reportedly for over $300 million.
A little-known fact: the market value of AI for medicine is far larger than that of AI for programming and office work. Anthropic may become the world's largest AI pharmaceutical company through acquisitions.